ABHRS President's Corner

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

Finasteride and a hair transplant were used to reverse hair loss, leading to thicker hair and increased confidence. The user received compliments on their improved appearance.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.

ABS-201 may block prolactin receptors in hair, potentially reducing androgen receptors and affecting hair loss. It could also aid collagen synthesis and stem cell pathways, similar to GHK-Cu.

The conversation is about the side effects of finasteride, including Post Finasteride Syndrome, with varied personal experiences and differing views on the credibility of information sources. Some participants also discuss using minoxidil as a hair loss treatment.